Omeros Corporation (OMER, Financial) experienced a significant stock decline of 6.17%, trading at $9.89 per share with a volume of 284,823 shares and a turnover rate of 0.49%. The company's recent financial report shows zero revenue, a net loss of $37.11 million, and an earnings per share of -$0.56. The gross profit stands at -$237,000, and the price-to-earnings ratio is -4.37. Among analysts, 33% recommend buying, while 67% suggest holding, with no sell recommendations.
Omeros, a clinical-stage biopharmaceutical company, focuses on developing therapies for immune diseases and other conditions. Its lead candidate, narsoplimab (OMS721), targets complement-mediated diseases.
